Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quanduzhong Jiaonang for knee osteoarthritis with hypertension
ChiCTR2300075332Phase 4Not yet recruiting
- Sponsor
- Third Affiliated Hospital, Beijing University of Chinese Medicine
- Start
- Jan 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Quanduzhong and tenghuang jiangu in knee osteoarthritis (OA) and essential hypertension (2 arms), sponsored by Third Affiliated Hospital, Beijing University of Chinese Medicine. Primary endpoint: Visual analogue scale score. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
Quanduzhongtenghuang jiangu
03
Conditions
knee osteoarthritis (OA)essential hypertension
Beyond the preview
Go deeper on ChiCTR2300075332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075332.